Izvestiya of Saratov University.

Chemistry. Biology. Ecology

ISSN 1816-9775 (Print)
ISSN 2541-8971 (Online)

For citation:

Savrasova V. I., Kulikova D. V., Razumova A. R., Andreeva K. O., Shtykov S. N. From structure to spectrum: A comprehensive spectral study of statins for solving pharmaceutical identification problems. Izvestiya of Saratov University. Chemistry. Biology. Ecology, 2026, vol. 26, iss. 3, pp. 248-260. DOI: 10.18500/1816-9775-2026-26-3-248-260, EDN: CRERPZ

This is an open access article distributed under the terms of Creative Commons Attribution 4.0 International License (CC-BY 4.0).
Full text:
download
(downloads: 41)
Language: 
Russian
Heading: 
Chemistry
Article type: 
Article
UDC: 
615.074:543.42 /.51:615.272.4
DOI: 
10.18500/1816-9775-2026-26-3-248-260
EDN: 
CRERPZ

From structure to spectrum: A comprehensive spectral study of statins for solving pharmaceutical identification problems

Autors: 
Savrasova Victoria Igorevna, Saratov State University
Kulikova Daria V., Saratov State University
Razumova Anastasia R. , Saratov State University
Andreeva Ksenia O., Saratov State University
Shtykov Sergey N., Saratov State University
Abstract: 

Statins, key drugs for the prevention of cardiovascular disease, are represented by a number of structurally diverse compounds requiring reliable identifi cation methods to ensure their quality control. This study, for the fi rst time, provides a comprehensive comparative analysis of all commercially signifi cant statins (lovastatin, simvastatin, pravastatin, fl uvastatin, atorvastatin, rosuvastatin, and pitavastatin) using complementary spectral methods: UV, FTIR (ATR), ¹H NMR spectroscopy, and mass spectrometry. Unique characteristics of each compound have been identifi ed and systematized, correlating with their structural features: the state of the acidic fragment in fi rst-generation statins and the type of heteroaromatic ring in synthetic analogs. Complete identifi cation profi les have been created, ensuring their unambiguous verifi cation. The results are of practical value for pharmacopoeial analysis, manufacturing control, and educational purposes.

Key words: 
statins
UV-
IR-
¹H NMR and mass spectra
identification
Reference: 
  1. Какорина Е. П., Никитина С. Ю. Особенности структуры смертности в Российской Федерации // Проблемы социальной гигиены, здравоохранения и истории медицины. 2019. Т. 27, № 5. С. 822–826. https://doi.org/10.32687/0869-866x-2019-27-5-822-826
  2. Golomb B. A., Dimsdale J. E., White H. L., Ritchie J. B., Criqui M. H. Reduction in blood pressure with statins: Results from the UCSD Statin Study, a randomized trial // Arch. Int. Med. 2008. Vol. 168, № 7. P. 721–727. https://doi.org/10.1001/archinte.168.7.721
  3. Fauchier L., Pierre B., Labriolle A., Grimard C., Zannad N., Babuty D. Antiarrhythmic effect of statin therapy and atrial fi brillation: A meta-analysis of randomized controlled trials // J. Amer. College Cardiol. 2008. Vol. 51, № 8. P. 828–835. https://doi.org/10.1016/j.jacc.2007.09.063
  4. Strazzullo P., Kerry S. M., Barbato A., Versiero M., D’Elia L., Cappuccio F. P. Do stati PIT ns reduce blood pressure? A meta-analysis of randomized, controlled trials // Hypertension. 2007. Vol. 49, № 4. P. 792–798. https://doi.org/10.1161/01.hyp.0000259737.43916.42
  5. Chróinín D. N., Asplund K., Åsberg S., Callaly E., Cuadrado-Godia E., Díez-Tejedor E., Di Napoli M., Engelter S. T., Furie K. L., Giannopoulos S., Gotto Jr A. M., Hannon N., Jonsson F., Kapral M. K., Martí-Fàbregas J., Martínez-Sánchez P., Milionis H. J., Montaner J., Muscari A., Pikija S., Probstfield J., Rost N. S., Thrift A. G., Vemmos K., Kelly P. J. Statin therapy and outcome after ischemic stroke: Systematic review and meta-analysis of observational studies and randomized trials // Stroke. 2013. Vol. 44, № 2. P. 448–456. https://doi.org/10.1161/strokeaha.112.668277
  6. Peltomaa A. I., Talala K., Taari K., Tammela T. L. J., Auvinen A., Murtola T. J. Inverse association between statin use and cancer mortality relates to cholesterol level // Cancers. 2022. Vol. 14, № 12. P. 2920. https://doi.org/10.3390/cancers14122920
  7. Han B. H., Sutin D., Williamson J. D., Davis B. R., Piller L. B., Pervin H., Pressel S. L., Blaum C. S. ALLHAT Collaborative Research Group Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: The ALLHAT-LLT randomized clinical trial // JAMA Int. Med. 2017. Vol. 177, № 7. P. 955–965. https://doi.org/10.1001/jamainternmed.2017.1442
  8. Cheung B. M. Y., Lauder I. J., Lau C. P., Kumana C. R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes // British J. Clin. Pharm. 2004. Vol. 57, № 5. P. 640–651. https://doi.org/10.1111/j.1365-2125.2003.02060.x
  9. Schooling C. M., Au Yeung S. L., Freeman G., Cowling B. J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials // BMC Med. 2013. Vol. 11, № 1. Art. 57. https://doi.org/10.1186/1741-7015-11-57
  10. García M. J., Reinoso R. F., Sánchez Navarro A., Prous J. R. Clinical pharmacokinetics of statins // Methods Findings Exper. Clin. Pharm. 2003. Vol. 25, № 6. P. 457–481.
  11. Hu M., Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin // Expert Opin. Drug Metabol. Toxicol. 2014. Vol. 10, № 1. P. 51–65. https://doi.org/10.1517/17425255.2014.851667
  12. Carswell C. I., Plosker G. L., Jarvis B. Rosuvastatin // Drugs. 2002. Vol. 62, № 14. Р. 2075–2085. https://doi.org/10.2165/00003495-200262140-00008
  13. Jeeyavudeen M. S., Pappachan J. M., Arunagirinathan G. Statin-related muscle toxicity: An evidencebased review // touchREVIEWS Endocrinol. 2022. Vol. 18, № 2. Art. 89. https://doi.org/10.17925/EE.2022.18.2.89
  14. Bellosta S., Paoletti R., Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions // Circulation. 2004. Vol. 109, № 23. Р. 50–57. https://doi.org/10.1161/01.CIR.0000131519.15067.1f
  15. Hirota T., Fujita Y., Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins // Expert Opin. Drug Metabol. Toxicol. 2020. Vol. 16, № 9. Р. 809–822. https://doi.org/10.1080/17425255.2020.1801634
  16. Piecha M., Sarakha M., Trebše P. Photocatalytic degradation of cholesterol-lowering statin drugs by TiO2-based catalyst. Kinetics, analytical studies and toxicity evaluation // J. Photochem. Photobiol. A: Chem. 2010. Vol. 213, № 1. Р. 61–69. https://doi.org/10.1016/j.jphotochem.2010.04.020
  17. Яжемская В. Я. Определение нафталина в воде спектрофотометрическим методом // Гигиена и санитария. 1964. № 11. С. 58–63.
  18. Yagil G. The proton dissociation constant of pyrrole, indole and related compounds // Tetrahedron. 1967. Vol. 23, № 6. P. 2855–2861. https://doi.org/10.1016/0040-4020(67)85151-2
  19. Hassan A. Saleem Y., Chaudhry M. N., Asghar A., Saleem M., Nawaz S., Syed Q., Iqbal M. S., Shahzad K. Optimization of process variables for increased production of lovastatin in Aspergillus terreus PUPCSIR1 and its characterization // Pakistan J. Pharm. Sci. 2019. Vol. 32, № 1. P. 363–370.
  20. Puttegowda V. D., Karki R., Goli D., Jha S. K., Mudagal M. P. Formulation and pharmacokinetic evaluation of microcapsules containing pravastatin sodium using rats // Scientifi ca. 2016. Vol. 2016, № 1. Art. 7623193. https://doi.org/0.1155/2016/7623193
  21. Da Silva E. P., Pereira M. A. V., Lima I. P. de B., Lima N. G. P. B., Barbosa E. G., Aragão C. F. S., Gomes A. P. B. Compatibility study between atorvastatin and excipients using DSC and FTIR // J. Thermal Anal. Calorim. 2016. Vol. 123, № 2. P. 933–939. https://doi.org/10.1007/s10973-015-5077-z
  22. Papageorgiou G. Z., Papadimitriou S., Karavas E., Georgarakis E., Docoslis A., Bikiaris D. Improvement in chemical and physical stability of fl uvastatin drug through hydrogen bonding interactions with different polymer matrices // Curr. Drug Deliv. 2009. Vol. 6, № 1. P. 101–112. https://doi.org/10.2174/156720109787048230
  23. Тарасевич Б. Н. ИК-спектры основных классов органических соединений : справочные материалы. M. : МГУ, 2012. 55 с.
  24. El-Din M. M. K. S., Attia K. A., Nassar M. W., Kaddah M. M. Colorimetric determination of simvastatin and lovastatin in pure form and in pharmaceutical formulations // Spectrochim. Acta Pt A: Mol. Biomol. Spectrosc. 2010. Vol. 76, № 3-4. P. 423–428. https://doi.org/10.1016/j.saa.2010.04.015
  25. Bhatia M. S., Jadhav S. D., Bhatia N. M., Choudhari P. B., Ingale K. B. Synthesis, characterization and quantifi cation of simvastatin metabolites and impurities // Scientia Pharm. 2011. Vol. 79, № 3. P. 601–614. https://doi.org/10.3797/scipharm.1105-16
  26. Kumar P. J., Muzib Y. I., Misra G. Formulation and evaluation of pulsatile drug delivery of lovastatin // Res. J. Pharm. Technol. 2018. Vol. 11, № 7. P. 2797–2803. https://doi.org/10.31032/IJBPAS/2024/13.5.8015
  27. Iffat W. S. M., Muhammad H. S., Rabia I. Y., Najia R., Abida S., Madiha M. Application and validation of analytical method for simultaneous determination of nicorandil and atorvastatin in bulk and tablet formulations // Lat. Am. J. Pharm. 2018. Vol. 37, № 8. P. 1510–1516.
  28. Shurshalova G. S., Yulmetov A. R., Sharapova D. A., Aganov A. V., Klochkov V. V. Interaction of lovastatin with model membranes by NMR data and from MD simulations // BioNanoSci. 2020. Vol. 10, № 2. P. 493–501. https://doi.org/10.1007/s12668-020-00722-4
  29. Rakhmatullin I. Z., Galiullina L. F., Klochkova E. A., Latfullin I. A., Aganov A.V., Klochkov V. V. Structural studies of pravastatin and simvastatin and their complexes with SDS micelles by NMR spectroscopy // J. Mol. Struct. 2016. Vol. 1105. P. 25–29. https://doi.org/10.1016/j.molstruc.2015.10.059
  30. Galiullina L. F., Aganova O. V., Latfullin I. A., Musabirova G., Aganov A. V., Klochkov V. V. NMR study of conformational structure of fl uvastatin and its complex with dodecylphosphocholine micelles // BioNanoSci. 2016. Vol. 6, № 4. P. 352–354. https://doi.org/10.1007/s12668-016-0232-y
  31. Galiullina L. F., Musabirova G. S., Latfullin I. A., Aganov A. V., Klochkov V. V. Spatial structure of atorvastatin and its complex with model membrane in solution studied by NMR and theoretical calculations // J. Mol. Struct. 2018. Vol. 1167. P. 69–77. https://doi.org/10.1016/j.molstruc.2018.04.012
  32. Beg S., Kaisar R., Rajendra K., Renu C., Om P., Bhupinder S. Improved intestinal lymphatic drug targeting via phospholipid complex-loaded nanolipospheres of rosuvastatin calcium // RSC Adv. 2016. Vol. 6, № 10. P. 8173–8187. https://doi.org/10.1039/C5RA24278A
  33. Wujian J., Kuan-Wei P., Sihyung Y., Huijing S., Mario S., Zhuo W. M. A simple protein precipitation-based simultaneous quantifi cation of lovastatin and its active metabolite lovastatin acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry using polarity switching // J. Chromatogr. Separ. Techn. 2015. Vol. 6, № 3. Art. 268. https://doi.org/10.4172/2157-7064.1000268
  34. Patel B. N., Sharma N., Sanyal M., Shrivastav P. S. Simultaneous determination of simvastatin and simvastatin acid in human plasma by LC-MS/MS without polarity switch: Application to a bioequivalence study // J. Separ. Sci. 2008. Vol. 31, № 2. P. 301–313. https://doi.org/10.1002/jssc.200700367
  35. Zhang X., Vernikovskaya D. I., Wang X., Nanovskaya T. N., Costantine M., Hankins G. D., Ahmed M. S. Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS // Biomed. Chromatogr. 2016. Vol. 30, № 4. P. 548–554. https://doi.org/10.1002/bmc.3581
  36. Huh Y., Plotka A., Wei H., Kaplan J., Raha N., Towner J., Purohit V. S., Dowty M. E., Wolk R., Vourvahis M., King-Ahmad A., Mathialagan S., West M. A., Lazzaro S., Ryu S., Rodrigues A. D. Utilization of rosuvastatin and endogenous biomarkers in evaluating the impact of ritlecitinib on BCRP, OATP1B1, and OAT3 transporter activity // Pharm. Res. 2023. Vol. 40, № 11. P. 2639–2651. https://doi.org/10.1007/s11095-023-03564-3
  37. Rysz M. A., Varanasi K., Veeraraghavan S., Arla R., Chennupati S., Rajamanickam M., Vakkalanka S., Khagga M. Simultaneous quantifi cation of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method // J. Pharm. Biomed. Anal. 2023. Vol. 236. Art. 115716. https://doi.org/10.1016/j.jpba.2023.115716
  38. Taillon M. P., Côté C., Furtado M., Garofolo F. Potentially new isobaric metabolite of fl uvastatin observed by LC–MS/MS during incurred sample analysis // Bioanalysis. 2011. Vol. 3, № 16. P. 1827–1835. https://doi.org/10.4155/bio.11.186
  39. Shen-Tu J., Xu X., Liu J., Hu X., Chen J., Wu L., Huang M., Zhou H. Determination of pitavastatin in human plasma by lc–ms–ms // Chromatographia. 2009. Vol. 69, № 9. P. 1041–1047. https://doi.org/10.1365/s10337-009-1006-2
Received: 
19.05.2026
Accepted: 
08.06.2026
Published: 
30.09.2026
Short text (in English):
download
(downloads: 23)